Phase II Proof-of-Concept Trial of the Orexin Receptor Antagonist Filorexant (MK-6096) in Patients with Major Depressive Disorder

Kathryn M Connor, Paulette Ceesay, Jill Hutzelmann, Duane Snavely, Andrew D Krystal, Madhukar H Trivedi, Michael Thase, Christopher Lines, W Joseph Herring, David Michelson, Kathryn M Connor, Paulette Ceesay, Jill Hutzelmann, Duane Snavely, Andrew D Krystal, Madhukar H Trivedi, Michael Thase, Christopher Lines, W Joseph Herring, David Michelson

Abstract

Background: We evaluated the orexin receptor antagonist filorexant (MK-6096) for treatment augmentation in patients with major depressive disorder.

Methods: We conducted a 6-week, double-blind, placebo-controlled, parallel-group, Phase II, proof-of-concept study. Patients with major depressive disorder (partial responders to ongoing antidepressant therapy) were randomized 1:1 to once-daily oral filorexant 10 mg or matching placebo.

Results: Due to enrollment challenges, the study was terminated early, resulting in insufficient statistical power to detect a prespecified treatment difference; of 326 patients planned, 129 (40%) were randomized and 128 took treatment. There was no statistically significant difference in the primary endpoint of change from baseline to week 6 in Montgomery Asberg Depression Rating Scale total score; the estimated treatment difference for filorexant-placebo was -0.7 (with negative values favoring filorexant) (P=.679). The most common adverse events were somnolence and suicidal ideation.

Conclusions: The interpretation of the results is limited by the enrollment, which was less than originally planned, but the available data do not suggest efficacy of orexin receptor antagonism with filorexant for the treatment of depression. (Clinical Trial Registry: clinicaltrials.gov: NCT01554176).

Keywords: MK-6096; depression; filorexant; orexin receptor antagonist.

© The Author 2017. Published by Oxford University Press on behalf of CINP.

References

    1. American Psychiatric Association (2000) Diagnostic and statistical manual of mental disorders. 4th ed, text revision. Washington, DC: American Psychiatric Association.
    1. Baglioni C, Riemann D (2012) Is chronic insomnia a precursor to major depression? Epidemiological and biological findings. Curr Psychiatry Rep 14:511–518.
    1. Bastien CH, Vallières A, Morin CM (2001) Validation of the insomnia severity index as an outcome measure for insomnia research. Sleep Med 2:297–307.
    1. Bent-Hansen J, Bech P (2011) Validity of the definite and semidefinite questionnaire version of the Hamilton Depression Scale, the Hamilton Subscale and the Melancholia Scale. Part I. Eur Arch Psychiatry Clin Neurosci 261:37–46.
    1. Berridge CW, Espana RA, Vittoz NM (2010) Hypocretin/orexin in arousal and stress. Brain Res 1314:91–102.
    1. Bettica P, Squassante L, Zamuner S, Nucci G, Danker-Hopfe H, Ratti E (2012) The orexin antagonist SB-649868 promotes and maintains sleep in men with primary insomnia. Sleep 35:1097–1104.
    1. Blanco C, Okuda M, Markowitz JC, Liu SM, Grant BF, Hasin DS (2010) The epidemiology of chronic major depressive disorder and dysthymic disorder: results from the National Epidemiologic Survey on Alcohol and Related Conditions. J Clin Psychiatry 71:1645–1656.
    1. Breslau N, Roth T, Rosenthal L, Andreski P (1996) Sleep disturbance and psychiatric disorders: a longitudinal epidemiological study of young adults. Biol Psychiatry 39:411–418.
    1. Coleman PJ, et al. (2012) Discovery of [(2R,5R)-5-{[(5-fluoropyridin-2-yl)oxy]methyl}-2-methylpiperidin-1-yl][5-methyl-2-(pyrimidin-2-yl)phenyl]methanone (MK-6096): a dual orexin receptor antagonist with potent sleep-promoting properties. ChemMedChem 7:415–424, 337.
    1. Connor KM, Mahoney E, Jackson S, Hutzelmann J, Zhao X, Jia N, Snyder E, Snavely D, Michelson D, Roth T, Herring WJ (2016) A phase II dose-ranging study evaluating the efficacy and safety of the orexin receptor antagonist filorexant (MK-6096) in patients with primary insomnia. Int J Neuropsychopharmacol 19:1–10. doi: 10.1093/ijnp/pyw022.
    1. Cruz HG, Hay JL, Hoever P, Alessi F, Te Beek ET, van Gerven JM, Dingemanse J (2014) Pharmacokinetic and pharmacodynamic interactions between almorexant, a dual orexin receptor antagonist, and desipramine. Eur Neuropsychopharmacol 24:1257–1268.
    1. Ferrari AJ, Charlson FJ, Norman RE, Patten SB, Freedman G, Murray CJ, Vos T, Whiteford HA (2010) Burden of depressive disorders by country, sex, age, and year: findings from the global burden of disease study PLoS Med 201310:e1001547.
    1. Fleurence R, Williamson R, Jing Y, Kim E, Tran QV, Pikalov AS, Thase ME (2009) A systematic review of augmentation strategies for patients with major depressive disorder. Psychopharmacol Bull 42:57–90.
    1. Gotter AL, Webber AL, Coleman PJ, Renger JJ, Winrow CJ (2012) International Union of Basic and Clinical Pharmacology. LXXXVI. Orexin receptor function, nomenclature and pharmacology. Pharmacol Rev 64:389–420.
    1. Hamilton M. (1960) A rating scale for depression. J Neurol Neurosurg Psychiatry 23:56–62.
    1. Herring WJ, Snyder E, Budd K, Hutzelmann J, Snavely D, Liu K, Lines C, Roth T, Michelson D (2012) Orexin receptor antagonism for treatment of insomnia: a randomized clinical trial of suvorexant. Neurology 79:2265–2274.
    1. Herring WJ, Connor KM, Ivgy-May N, Snyder E, Liu K, Snavely D, Krystal AD, Walsh JK, Benca RM, Rosenberg R, Sangal RB, Budd K, Hutzelmann J, Leibensperger H, Froman S, Lines C, Roth T, Michelson D (2016) Suvorexant in patients with insomnia: results from two 3-month randomized controlled clinical trials. Biol Psychiatry 79:136–148.
    1. Hoever P, et al. (2012) Orexin receptor antagonism, a new sleep-enabling paradigm: a proof-of-concept clinical trial. Clin Pharmacol Ther 91:975–985.
    1. Kukkonen JP, Leonard CS (2014) Orexin/hypocretin receptor signalling cascades. Br J Pharmacol 171:314–331.
    1. Michelson D, Snyder E, Paradis E, Chengan-Liu M, Snavely DB, Hutzelmann J, Walsh JK, Krystal AD, Benca RM, Cohn M, Lines C, Roth T, Herring WJ (2014) Safety and efficacy of suvorexant during 1-year treatment of insomnia with subsequent abrupt treatment discontinuation: a phase 3 randomised, double-blind, placebo-controlled trial. Lancet Neurol 13:461–471.
    1. Mikrouli E, Wortwein G, Soylu R, Mathe AA, Petersen A (2011) Increased numbers of orexin/hypocretin neurons in a genetic rat depression model. Neuropeptides 45:401–406.
    1. Montgomery SA, Asberg M (1979) A new depression scale designed to be sensitive to change. Br J Psychiatry 134:382–389.
    1. Moore HK, Mundt JC, Modell JG, Rodrigues HE, DeBrota DJ, Jefferson JJ, Greist JH (2006) An examination of 26,168 Hamilton Depression Rating Scale scores administered via interactive voice response across 17 randomized clinical trials. J Clin Psychopharmacol. 26:321–324.
    1. Nollet M, Gaillard P, Minier F, Tanti A, Belzung C, Leman S (2011) Activation of orexin neurons in dorsomedial/perifornical hypothalamus and antidepressant reversal in a rodent model of depression. Neuropharmacology 61:336–346.
    1. Papakostas GI, Perlis RH, Scalia MJ, Petersen TJ, Fava M (2006) A meta-analysis of early sustained response rates between antidepressants and placebo for the treatment of major depressive disorder. J Clin Psychopharmacol 26:56–60.
    1. Posner K, Brown GK, Stanley B, Brent DA, Yershova KV, Oquendo MA, Currier GW, Melvin GA, Greenhill L, Shen S, Mann JJ (2011) The Columbia-Suicide Severity Rating Scale: initial validity and internal consistency findings from three multisite studies with adolescents and adults. Am J Psychiatry 168:1266–1277.
    1. Salomon RM, Ripley B, Kennedy JS, Johnson B, Schmidt D, Zeitzer JM, Nishino S, Mignot E (2003) Diurnal variation of cerebrospinal fluid hypocretin-1 (orexin-A) levels in control and depressed subjects. Biol Psychiatry 54:96–104.
    1. Schmidt FM, Arendt E, Steinmetzer A, Bruegel M, Kratzsch J, Strauss M, Baum P, Hegerl U, Schönknecht P (2011) CSF-hypocretin-1 levels in patients with major depressive disorder compared to healthy controls. Psychiatry Res 190:240–243.
    1. Sheehan DV, Lecrubier Y, Sheehan KH, Amorim P, Janavs J, Weiller E, Hergueta T, Baker R, Dunbar GC (1998) The mini-international neuropsychiatric interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. J Clin Psychiatry 59:22–33.
    1. Sinyor M, Levitt AJ, Cheung AH, Schaffer A, Kiss A, Dowlati Y, Lanctot KL (2010) Does inclusion of a placebo arm influence response to active antidepressant treatment in randomized controlled trials? Results from pooled and meta-analyses. J Clin Psychiatry 71: 270–279.
    1. Staner L. (2010) Comorbidity of insomnia and depression. Sleep Med Rev 14:35–46.
    1. Walsh BT, Seidman SN, Sysko R, Gould M (2002) Placebo response in studies of major depression: variable, substantial, and growing. JAMA 287:1840–1847.
    1. Winrow CJ, Gotter AL, Cox CD, Tannenbaum PL, Garson SL, Doran SM, Breslin MJ, Schreier JD, Fox SV, Harrell CM, Stevens J, Reiss DR, Cui D, Coleman PJ, Renger JJ (2012) Pharmacological characterization of MK-6096 - a dual orexin receptor antagonist for insomnia. Neuropharmacology 62:978–987.
    1. Winrow CJ, Renger JJ (2014) Discovery and development of orexin receptor antagonists as therapeutics for insomnia. Br J Pharmacol 171:283–293.
    1. Yeoh JW, Campbell EJ, James MH, Graham BA, Dayas CV (2014) Orexin antagonists for neuropsychiatric disease: progress and potential pitfalls. Front Neurosci 8:36.

Source: PubMed

Patrocinadores e Colaboradores

Condições médicas

Intervenções de drogas

3
Se inscrever